Digest Network Come funziona
Network
/
Società
Gi
Non verificato

Gilead Sciences, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteSanità

145 comunicati stampa

Guarda tutti i comunicati
16/09/2026
Biotecnologia
HIV, AIDS e malattie autoimmuni
Sanità
Salute
Farmaceutica
Industria
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
15/09/2026
Scienza
HIV, AIDS e malattie autoimmuni
Sanità
Medicina - Varie
Biotecnologia
Farmaceutica
Salute
Mercato del lavoro
Industria
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
08/09/2026
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
27/08/2026
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
26/08/2026
Web e Social Network
Fiere
Eventi
Biotecnologia
Sanità
Farmaceutica
Salute
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
24/08/2026
Industria
Scienza
Sanità
Igiene alimentare
Medicina - Varie
Biotecnologia
Farmaceutica
Salute
Oncologia
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
05/08/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Igiene alimentare
Sanità
Medicina - Varie
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
04/08/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Igiene alimentare
Sanità
Medicina - Varie
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
Gilead Sciences Announces Second Quarter 2026 Financial Results
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
24/07/2026
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
21/07/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Sanità
Farmaceutica
Salute
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0